Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nanobiotix ( (NBTX) ) has shared an update.
On December 15, 2025, Nanobiotix announced its inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective after the market closes on December 19, 2025. This inclusion is expected to enhance the company’s visibility among institutional investors, strengthen its presence in European equity markets, and increase exposure to index-linked investment strategies, reflecting market confidence in its long-term strategy and innovative nanotherapeutic solutions.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, with a focus on pioneering physics-based therapeutic approaches to improve treatment outcomes for cancer and other major diseases. Founded in 2003, the company is listed on Euronext Paris and the Nasdaq Global Select Market, and it holds over 25 umbrella patents related to nanotechnology platforms in oncology, bioavailability, biodistribution, and central nervous system disorders.
Average Trading Volume: 103,045
Technical Sentiment Signal: Buy
Current Market Cap: $1.1B
For an in-depth examination of NBTX stock, go to TipRanks’ Overview page.